In vitro neutralization of antigenic variants of bluetongue virus is related to in vivo protection.
Neutralization resistant variants of bluetongue virus serotype 10 were selected with a neutralizing monoclonal antibody. Three variants were selected for further characterization. One of these variants was completely resistant to neutralization, while the other two variants showed intermediate resistance to neutralization as compared to the parent virus. The completely resistant variant failed to bind the selecting monoclonal antibody as determined by immune precipitation and enzyme linked immunosorbent assay; whereas, the other two variants bound antibody to a similar extent as the parent virus as determined by these tests. The ability of the variants to bind monoclonal antibody correlated with passive protection in the newborn mouse model. These results indicate that the ability of the virus to bind antibody is directly related to in vivo protection and that in vitro neutralization and in vivo protection are also related.